Back to School: How biopharma can reboot drug development. Access exclusive analysis here

InterCell: Viennese vaccines play

While many start-up biotech companies employ either a single platform technology, or multiple disciplines that are not necessarily related, Intercell GmbH has opted for a middle ground. The company applies its Cistem screening technology to identify vaccine candidate molecules and then uses these molecules in its Transvax platform to generate vaccines.

With these two complementary technologies, Intercell hopes to develop vaccines in the areas of cancer and infectious diseases. Intercell

Read the full 706 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers